GILUPI
Key Facts
| Invested since | 2006 |
About the company
GILUPI GmbH is a medical device company with focus on the development and production of innovative products for the in vivo isolation of rare cells from the circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies will become more and more important in tomorrow’s personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector™ enriches rare cells (circulating tumor cells- CTCs) by directly “fishing” them in the patient’s bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level. Thus, statements regarding the current status of the disease or/and the prognosis can be made. In addition, the physician is able to adjust the treatment immediately and optimize the therapy of the patient.
The GILUPI CellCollector™ is the first in vivo CTC isolation product worldwide with CE approval.
Do you want to
know more about this company?
GILUPI in the news
Zum Artikel
The GILUPI GmbH is expanding to the Asian markets and received the CE-certificate for its CellCollector
Zum Artikel
Third round financing for GILUPI GmbH with Aurelia Private Equity, Brandenburg Capital (BFBII), KfW Bankengruppe and High-Tech Gründerfonds
More startups from Life Sciences
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
The core competency of AQ Implants GmbH is the endoprosthetic reconstruction of severe and complex defects and anomalies. With the development of innovative implant systems AQ Implants GmbH provides surgeons …
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life …
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
LignoPure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. …
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg’s “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The …
